ArticleThe American journal of pathology1998
Complement-mediated killing of microtumors in vitro.
Article in The American journal of pathology, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Towards antibody-based immunotherapy development for platinum-resistant high-grade serous ovarian cancer.Scientific reports · 2025Article
- Ovo Like Zinc Finger 2 (OVOL2) Suppresses Breast Cancer Stem Cell Traits and Correlates with Immune Cells Infiltration.Breast cancer (Dove Medical Press) · 2022Article
- Comprehensive Analysis of Prognostic Microenvironment-Related Genes in Invasive Breast Cancer.Frontiers in oncology · 2021Article
- Tumor-Derived Tissue Factor Aberrantly Activates Complement and Facilitates Lung Tumor Progression via Recruitment of Myeloid-Derived Suppressor Cells.International journal of molecular sciences · 2017Article
- A review of therapeutic aptamer conjugates with emphasis on new approaches.Pharmaceuticals (Basel, Switzerland) · 2013Article
- Dynamics and visualization of MCF7 adenocarcinoma cell death by aptamer-C1q-mediated membrane attack.Nucleic acid therapeutics · 2012Article
- gC1qR expression in normal and pathologic human tissues: differential expression in tissues of epithelial and mesenchymal origin.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2012Article
- Aptamer–biotin–streptavidin–C1q complexes can trigger the classical complement pathway to kill cancer cells.In vitro cellular & developmental biology. Animal · 2010Article
- Complement susceptibility in glutamine deprived breast cancer cells.Cell division · 2007Article
- The pattern of clinical breast cancer metastasis correlates with a single nucleotide polymorphism in the C1qA component of complement.Immunogenetics · 2006Article
- Expression of complement protein C5a in a murine mammary cancer model: tumor regression by interference with the cell cycle.Cancer immunology, immunotherapy : CII · 2005Article
- Ascitic complement system in ovarian cancer.British journal of cancer · 2005Article
- Expression of complement regulating factors in gastric cancer cells.Molecular pathology : MP · 2002Article
- Overexpression of clusterin in human breast carcinoma.The American journal of pathology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complement-mediated lysis of cancer cells growing in three-dimensional aggregates involves factors that are not associated with the killing of cells in suspension. We have used multicellular tumor spheroids established from breast carcinoma (T47D) and ovarian teratocarcinoma (PA-1) cell lines as models to study complement-mediated destruction of micrometastases and small solid tumors. We found that significant killing of microtumors treated with an antitumor antibody and a specific monoclonal antibody (YTH53.1) against the complement lysis inhibitor protectin (CD59) started to occur after a 1 to 2-hour lag phase. After an overnight incubation, the microtumors became totally infiltrated by the YTH53.1 monoclonal antibody and C1q, whereas C3 and C5b-9 penetrated as a frontier to the peripheral cell layers. A 51Cr release assay showed that during a 24-hour pulsed treatment with complement, 33% of cells in the spheroids were killed, and the average tumor volume decreased by 28%. According to propidium iodide staining, complement exposure resulted in killing and peeling off of the outermost tumor cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.